Jacqueline Lehmann

Statistics

Publications

Citations

178

H-Index

Active since

2005

Affiliations

Institut universitaire du cancer de Toulouse Oncopole(Current)

Centre Henri Becquerel

Moffitt Cancer Center

Centre Hospitalier Universitaire de Lille

Assistance Publique – Hôpitaux de Paris

Jacqueline Lehmann is an author at Institut universitaire du cancer de Toulouse Oncopole specializing in medicine, hematologic malignancy pharmacotherapy, and acute myeloid leukemia therapy.

Publications per year

2005–2021

Publications

APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)

Thomas Cluzeau, Marie Sébert, Ramy Rahmé et al. · Blood · 2019 · 65 citations

Medicine, Oncology, Pharmacotherapy +16

Brain structure is changed in congenital anosmia

Johannes Frasnelli, Therese Fark, Jacqueline Lehmann et al. · NeuroImage · 2013 · 60 citations

Medicine, Neurobiology, Neuroscience +13

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with <i>TP53</i> mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

David A. Sallman, Rami S. Komrokji, Amy E. DeZern et al. · Blood · 2021 · 41 citations

Medicine, Oncology, Pharmacology +16

A phase II trial of pemetrexed plus gemcitabine as first-line treatment for locally advanced or metastatic transitional cell carcinoma of the urothelium

Hans von der Maase, Jacqueline Lehmann, Gwénaëlle Gravis et al. · Journal of Clinical Oncology · 2005 · 12 citations

Medicine, Pharmacology, Urologic Oncology +1

1–4 of 4